While further analysis of trial data confirms efficacy and safety events in real-world practice continue to be monitored, the attitude of retina specialists toward the newest FDA-approved anti-VEGF agent remains open but cautious.
“Brolucizumab is, at this stage, a risk-benefit question,” Nancy M. Holekamp, MD, said.
Welcomed with high expectations, Beovu (brolucizumab, Novartis) had positive initial feedback from early users, until cases of severe sight-threatening side effects were reported, derailing the drug’s initial launch.
“The question is whether it is worth
Uncategorized